USANA Health Sciences Inc. Common Stock (USNA)

FairStock Score: 35/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I see a low-price asset situation, not yet a proven business. USANA sells nutritional, personal-care, and skincare products, but the numbers show deteriorating earning power. Fiscal Q2 2026, the quarter ended 2026-07-04, produced revenue of $223.3 million and a net loss of $21.4 million, or diluted EPS of -$1.16; fiscal Q2 2025, the quarter ended 2025-06-28, had revenue of $235.8 million, net income of $9.7 million, and EPS of $0.52. For FY2025, the year ended 2026-01-03, revenue was $925.3 million, net income $10.8 million, and diluted EPS $0.58, down from FY2024 net income of $42.0 million and EPS of $2.19. That is not the stable consumer-franchise profile I want. The balance sheet is a genuine strength: debt-to-equity is 0.02 and Altman Z-score is 2.73 per FairStock. The stock closed at $14.04 on 2026-10-26 at 0.49x book and 2.14x EV/EBITDA per FairStock, with TTM FCF of $15.9 million and a 6.1% FCF yield. FairStock calls it an asset play at 0.54x book. Cheap on assets can be a starting point, but negative ROE of -5.06%, a Piotroski F-score of 4/9, and a 35/100 FairStock score say the turnaround is unproven. I would need evidence that earnings and cash flow are durable before treating book value as protection rather than a value trap.

In plain English: USANA sells nutritional supplements, personal-care products, and skincare. The business looks weak now: it lost money in the latest quarter and profits have fallen sharply. The stock price looks low compared with the company's stated net worth, but weak earnings make the cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-07-04) · fiscal Q1 2026 10-Q (period ended 2026-04-04) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2026-01-03) · FY2024 10-K (period ended 2024-12-28) · FY2023 10-K (period ended 2023-12-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer